News

• 14 July 2020News UpdateTLA for enhanced Apollo X CHO clone screening...Read more
• 29 June 2020Press ReleaseCergentis appoints new CEO and Board members...Read more
• 20 May 2020News UpdateNovalis Biotech Incubation to invest in CergentisNovalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount....Read more
• 30 April 2020Press ReleaseGenedata - Cergentis partnership for automation TLA data analysis workflow...Read more
• 20 April 2020News UpdateAutomated TLA protocol: new PerkinElmer & Cergentis application note...Read more
• 16 March 2020News UpdateCOVID-19In light of the ongoing COVID-19 outbreak, we wish to briefly update you......Read more

• 6 January 2020News UpdateLaunch new websiteNew year, new website...Read more
• 12 December 2019Press ReleaseCergentis launches TLA technology for complete cancer gene mutation sequencingUTRECHT, THE NETHERLANDS - 07:00 CET, December 12, 2019 - Cergentis, a genomics company that develops and commercialises kits and services based on its propriet...Read more
• 1 November 2019News UpdateCergentis appoints new CFOIt is a true pleasure to announce that Jean-Marc Roelandt has joined Cergentis as Chief Financial Officer. Jean-Marc is a senior level executive with more than ...Read more
• 16 September 2019Press ReleaseCergentis appoints new boardUtrecht, The Netherlands - September 16, 2019. Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targete...Read more